iRhythm Holdings, Inc. IRTC

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how patient monitoring stocks fared in Q2, starting with iRhythm (NASDAQ:IRTC).

317-Page Report Maps Patch, Smartwatch, and Handheld ECG Devices as Regulatory Clearances and AI-Powered Arrhythmia Detection Reshape Cardiac Monitoring Outside the ClinicDublin, Sept. 04, 2026 (GLOBE NEWSWIRE) -- The "Smart Wearable ECG Monitors Market Size, Share & Trends Analysis, - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering. Market Size and Forecast The global smart wearable ECG monitors market is estimated to be valued at USD 2.4 billion in 2026 and is proj

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference. iRhythm’s management is scheduled to present on Wednesday, September 9, 2026, at 8:45 a.m. ET. Interested parties may access a live and archived webcast of the fireside chat on the “Events

iRhythm Holdings (IRTC) informed investors that Board member and Audit Committee chair Brian Yoor resigned for personal reasons on August 12, 2026. Existing director Karen McGinnis will step in to chair the Audit Committee. iRhythm Holdings’ share price has been volatile over 2026, with a 30 day share price return of 12.72% and a 7 day gain of 6.81%. However, the year to date share price return is down 29.75% and the 1 year total shareholder return is down 26.74%, even though the 5 year total...

Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few under-the-radar businesses will continue prospering by anchoring themselves in unique market segments.

iRhythm’s stock price has taken a beating over the past six months, shedding 27.5% of its value and falling to $115.17 per share. This may have investors wondering how to approach the situation.

iRhythm’s second quarter results were met with a strong positive market reaction, reflecting the company’s ability to deliver both robust revenue growth and significant margin improvement. Management attributed this performance to sustained demand for the Zio ambulatory cardiac monitoring platform and effective commercial execution across cardiology, primary care, and new healthcare channels. CEO Quentin Blackford noted that the company’s operational discipline and successful integration of digi

Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) fell 2.8% in the afternoon session after a significant price target cut from an analyst overshadowed the company's strong quarterly earnings report.

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 2% in the afternoon session after the company reported strong second-quarter financial results that surpassed expectations and raised its full-year guidance.

iRhythm (IRTC) could benefit from stronger sales growth, wider access to the cardiac monitoring mark

Acquiring VitalConnect could unlock a $1 billion cardiac monitoring market that is only partly served by iRhythm’s existing devices.